发明名称 Chronic rejection inhibitor
摘要 The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.
申请公布号 US9562103(B2) 申请公布日期 2017.02.07
申请号 US200812524041 申请日期 2008.01.23
申请人 Chugai Seiyaku Kabushiki Kaisha;Shinshu University 发明人 Takahashi Masafumi;Izawa Atsushi
分类号 A61K39/395;C07K16/28;A61K39/00 主分类号 A61K39/395
代理机构 Sterne, Kessler, Goldstein & Fox P.L.L.C. 代理人 Sterne, Kessler, Goldstein & Fox P.L.L.C.
主权项 1. A method for suppressing chronic rejection reaction, which comprises administering a composition comprising an antibody that recognizes an IL-6 receptor to a subject in need thereof prior to organ transplantation, at the time of organ transplantation, or after organ transplantation, thereby suppressing chronic rejection reaction in the subject with a transplanted organ after the organ transplantation, wherein the antibody that recognizes an IL-6 receptor is the only active ingredient in the composition.
地址 Tokyo JP